Tillgång till information är en investerares grundläggande rättighet

Today, we hosted an event with CEO Carsten Drachmann, where he presented the FY 2025 results and outlook for 2026. The focus was also on where the markets are moving in the coming years and how GomSpace is aligning with this strategic outlook. The event concluded with a Q&A session.

Today, ExpreS2ion Biotechnologies’ management presented the financial results for the FY 2025, provided further insights into the recent pipeline developments with focus on the malaria, Niphah and breast cancer candidates, and shared the latest updates on partnerships agreements

Vi har publicerat en Aktiebrief om Upsales, baserat på bolagets Q4'25-rapport. Läs hela briefen via länken.

8:22

Revenue development fell short of our expectations, but Anora improved its adjusted EBITDA.

GomSpace is expected to release its Q4 2025 interim report and full-year results on 19 February 2026. On the same day at 11:00 CET, GomSpace’s CEO, Carsten Drachmann, will present the results for the fourth quarter and the full year 2025 in a live online event, followed by a Q&A session.

ExpreS2ion Biotechnologies expects to publish its full-year report for 2025 (Q4) on 19 February 2026. Later the same day at 09:30, the company’s management will present the results for the financial year, provide an update on business and pipeline developments, and follow up on recent company news in a live online event, which will conclude with a Q&A session.

Starbreeze levererade en omsättning för Q4 som var tydligt under vår förväntning, där avvikelsen främst berodde på ett svagare bidrag från PAYDAY 3.

Marginalen och kassaflödet var starkare än förväntat. Guidningen väntas vara i linje med förväntningarna.

Witteds Q4 var ett steg i rätt riktning, men antalet specialister i början av året var lägre än våra förväntningar.